Ann: PanCO Clinical Study on OncoSil Published in ESMO Open, page-8

"Ten patients (20.0% ITT; 23.8% PP) had surgical resection " -Ross P.J, Wasan H.S, Croagh D et. al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy, ESMO Open, 2021, 7(1) https://doi.org/10.1016/j.esmoop.2021.100356.

So a difference of 3.8% for surgical resection, which once again, isn't great and is also possibly a statistical anomaly due to the strength of the sample size (if they ran the study 100 times, I would bet money on it that many of those studies would yield negative results).

I am not saying they did anything wrong by having a small sample size, the truth is, you often get small sample sizes for rare cancer studies.

All I am saying is, if I was big pharma, I wouldn't care in the slightest by a 3.8% increase in surgical resection, or an increase of 0.3month median overall survival. And that is probably why they didn't sell anything, because the studies did not yield compelling evidence.